![](/images/graphics-bg.png)
Diagnostic and Prognostic Potentials of Long Noncoding RNA ELF3-AS1 in Glioma Patients
Joint Authors
Mei, Jun-chi
Yan, Ge
Mei, Si-qing
Source
Issue
Vol. 2020, Issue 2020 (31 Dec. 2020), pp.1-7, 7 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2020-09-18
Country of Publication
Egypt
No. of Pages
7
Main Subjects
Abstract EN
Objective.
Accumulating evidence implies that long noncoding RNAs (lncRNAs) play a crucial role in predicting survival for glioma patients.
However, the potential function of lncRNA ELF3-antisense RNA 1 (ELF3-AS1) in tumors remained largely unclear.
The aim of this study was to explore the expression of lncRNA ELF3-antisense RNA 1 (ELF3-AS1) and evaluate its functions in glioma patients.
Patients and Methods.
ELF3-AS1 expressions were examined by RT-PCR in 182 pairs of glioma specimens and adjacent normal tissues.
The receiver operating characteristic (ROC) curve was performed to estimate the diagnostic value of ELF3-AS1.
The chi-square tests were used to examine the associations between ELF3-AS1 expression and the clinicopathological characters.
The overall survival (OS) and disease-free survival (DFS) were analyzed by log-rank test, and survival curves were plotted according to Kaplan-Meier.
The prognostic value of the ELF3-AS1 expression in glioma patients was further analyzed using univariate and multivariate Cox regression analyses.
Loss-of-function assays were performed to determine the potential function of ELF3-AS1 on the proliferation and invasion of glioma cells.
Results.
The ELF3-AS1 expression level was significantly higher in glioma specimens compared with adjacent nontumor specimens (p<0.01).
A high expression of ELF3-AS1 was shown to be associated with the WHO grade (p=0.023) and KPS score (p=0.012).
ROC assays revealed that high ELF3-AS1 expression had an AUC value of 0.8073 (95% CI: 0.7610 to 0.8535) for glioma.
Using the Kaplan-Meier analysis, we found that patients with a high ELF3-AS1 expression had significantly poor OS (p=0.006) and DFS (p=0.0002).
In a multivariate Cox model, we confirmed that ELF3-AS1 expression was an independent poor prognostic factor for glioma patients.
The functional assay revealed that knockdown of ELF3-AS1 suppressed the proliferation and invasion of glioma cells.
Conclusions.
Our findings confirmed that ELF3-AS1 functions as an oncogene in glioma and indicated that ELF3-AS1 is not only an important prognostic marker but also a potential therapy target for glioma.
American Psychological Association (APA)
Mei, Jun-chi& Yan, Ge& Mei, Si-qing. 2020. Diagnostic and Prognostic Potentials of Long Noncoding RNA ELF3-AS1 in Glioma Patients. Disease Markers،Vol. 2020, no. 2020, pp.1-7.
https://search.emarefa.net/detail/BIM-1154156
Modern Language Association (MLA)
Mei, Jun-chi…[et al.]. Diagnostic and Prognostic Potentials of Long Noncoding RNA ELF3-AS1 in Glioma Patients. Disease Markers No. 2020 (2020), pp.1-7.
https://search.emarefa.net/detail/BIM-1154156
American Medical Association (AMA)
Mei, Jun-chi& Yan, Ge& Mei, Si-qing. Diagnostic and Prognostic Potentials of Long Noncoding RNA ELF3-AS1 in Glioma Patients. Disease Markers. 2020. Vol. 2020, no. 2020, pp.1-7.
https://search.emarefa.net/detail/BIM-1154156
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1154156